In many ways, executives of start-ups developing insulin pumps have it easy when raising capital. They don't have to sell venture capitalists on the market. Across the world, 220 million people have diabetes (24 million just in the US) and that number is projected to grow to more than 400 million by the year 2030. The product is a pump, a simple technology in an industry rich with untested devices. And the chief therapeutic agent – insulin – is a known treatment that's well-received by physicians and patients alike, at least in terms of effectiveness.
Insulin delivery companies don't need to wrestle with any scientific or clinical unknowns. The goals for managing the disease are...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?